MSCL Stock Overview
Satellos Bioscience Inc., a biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Satellos Bioscience Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.44 |
| 52 Week High | CA$0.80 |
| 52 Week Low | CA$0.29 |
| Beta | 1.09 |
| 1 Month Change | -4.35% |
| 3 Month Change | -6.38% |
| 1 Year Change | -40.54% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -75.42% |
Recent News & Updates
Shareholder Returns
| MSCL | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | -10.2% | 0.4% | 0.7% |
| 1Y | -40.5% | -37.2% | 4.9% |
Return vs Industry: MSCL underperformed the Canadian Biotechs industry which returned -38.2% over the past year.
Return vs Market: MSCL underperformed the Canadian Market which returned 5.5% over the past year.
Price Volatility
| MSCL volatility | |
|---|---|
| MSCL Average Weekly Movement | 13.8% |
| Biotechs Industry Average Movement | 13.3% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in CA Market | 18.1% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: MSCL's share price has been volatile over the past 3 months.
Volatility Over Time: MSCL's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | Frank Gleeson | satellos.com |
Satellos Bioscience Inc., a biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases. Its lead program focuses on the discovery and development of a small molecule drug for the treatment of duchenne. The company’s MyoReGenX, an automated microscopy system which recapitulates the muscle stem cell environment ex-vivo.
Satellos Bioscience Inc. Fundamentals Summary
| MSCL fundamental statistics | |
|---|---|
| Market cap | CA$49.63m |
| Earnings (TTM) | -CA$15.89m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.1x
P/E RatioIs MSCL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MSCL income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$8.82m |
| Gross Profit | -CA$8.82m |
| Other Expenses | CA$7.07m |
| Earnings | -CA$15.89m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.14 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MSCL perform over the long term?
See historical performance and comparison